Name | Role | Date | Shares | Price | Value |
---|---|---|---|---|---|
Thomas J. Errico | Director | 2025-08-11 | 15,000 | $4.47 | $67.05kBuy |
Daniel S. Goldberger | Chief Executive Officer | 2025-08-11 | 1,000 | $4.23 | $4.23kBuy |
John P. Gandolfo | Director | 2025-05-23 | 1,800 | $5.01 | $9.02kBuy |
Thomas J. Errico | Director | 2025-05-12 | 10,000 | $4.77 | $47.74kBuy |
Thomas J. Errico | Director | 2025-03-17 | 6,000 | $8.10 | $48.59kBuy |
Daniel S. Goldberger | Chief Executive Officer | 2025-03-17 | 1,000 | $8.59 | $8.59kBuy |
Name | Hold | Shares | Value | Type |
---|---|---|---|---|
Joseph P. Errico | 50.93% | 3,861,942 | $20.24M | Insider |
Merck Global Health Innovation Fund LLC | 44.12% | 3,346,032 | $17.53M | Insider |
James L. L. Tullis | 26.56% | 2,014,110 | $10.55M | Insider |
Thomas J. Errico | 13.01% | 986,491 | $5.17M | Insider |
Core Ventures II LLC | 8.52% | 646,342 | $3.39M | Insider |
Peter S. Staats | 6.28% | 476,419 | $2.50M | Insider |
Charles Steve Theofilos | 6.10% | 462,758 | $2.42M | Insider |
Francis R. Amato | 4.86% | 368,355 | $1.93M | Insider |
Daniel S. Goldberger | 3.84% | 291,565 | $1.53M | Insider |
Vanguard Group Inc | 3.06% | 232,333 | $1.22M | Institution |